Expansion of Indications for an Immunomodulatory Treatment in Diabetes
The UAE health authorities have announced the expansion of the use of an immune therapy for Type 1 diabetes, allowing its use now to delay the onset of the third stage of the disease in children starting from one year old, and to improve disease management in children and adolescents aged 8 to 17 years who have been recently diagnosed. This advancement represents a major medical milestone since the discovery of insulin, aiming to slow the decline in natural insulin production and enhance care for Type 1 diabetes patients.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)